Effects of formulation design on niacin therapeutics: mechanism of action, metabolism, and drug delivery
- 1 July 2015
- journal article
- review article
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 490 (1-2) , 55-64
Abstract
No abstract availableKeywords
This publication has 80 references indexed in Scilit:
- A case for immediate-release niacinHeart & Lung, 2012
- HDL-C: Role as a risk modifierAtherosclerosis Supplements, 2011
- Important Considerations for Treatment with Dietary Supplement versus Prescription Niacin ProductsPostgraduate Medicine, 2011
- Triglycerides and HDL CholesterolDiabetes Care, 2009
- Editorials: Niacin and Related Compounds for Treating Hyperphosphatemia in Dialysis PatientsSeminars in Dialysis, 2008
- Lipid-Lowering Agents That Cause Drug-Induced HepatotoxicityClinics in Liver Disease, 2007
- Lipoprotein(a)Arteriosclerosis, Thrombosis, and Vascular Biology, 2004
- Extended-release niacin/lovastatin: the first combination product for dyslipidemiaExpert Review of Cardiovascular Therapy, 2004
- Comparison of Once-Daily, niacin Extended-Release/lovastatin with standard doses of atorvastatin and simvastatin (the advicor versus other Cholesterol-Modulating agents trial evaluation [ADVOCATE])The American Journal of Cardiology, 2003
- Interaction of Tablet Disintegrants and Magnesium Stearate during Mixing I: Effect on Tablet DisintegrationJournal of Pharmaceutical Sciences, 1981